Tags

Type your tag names separated by a space and hit enter

Mesenchymal stem cells: current clinical progress in ARDS and COVID-19.
Stem Cell Res Ther. 2020 07 22; 11(1):305.SC

Abstract

Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologically active factors. In this review, we will focus on clinical progress in the use of MSCs as a cell therapy for ARDS, which may have clinical implications during the coronavirus disease 2019 (COVID-19) pandemic.

Authors+Show Affiliations

Department of Pulmonary and Critical Care Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China. Medical School of Chinese People's Liberation Army (PLA), Beijing, China.Department of Pulmonary and Critical Care Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China. Medical School of Chinese People's Liberation Army (PLA), Beijing, China.Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. qianzhir@mail.sysu.edu.cn.Department of Pulmonary and Critical Care Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China. xielx301@126.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32698898

Citation

Xiao, Kun, et al. "Mesenchymal Stem Cells: Current Clinical Progress in ARDS and COVID-19." Stem Cell Research & Therapy, vol. 11, no. 1, 2020, p. 305.
Xiao K, Hou F, Huang X, et al. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. Stem Cell Res Ther. 2020;11(1):305.
Xiao, K., Hou, F., Huang, X., Li, B., Qian, Z. R., & Xie, L. (2020). Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. Stem Cell Research & Therapy, 11(1), 305. https://doi.org/10.1186/s13287-020-01804-6
Xiao K, et al. Mesenchymal Stem Cells: Current Clinical Progress in ARDS and COVID-19. Stem Cell Res Ther. 2020 07 22;11(1):305. PubMed PMID: 32698898.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. AU - Xiao,Kun, AU - Hou,Fei, AU - Huang,Xiuyu, AU - Li,Binbin, AU - Qian,Zhi Rong, AU - Xie,Lixin, Y1 - 2020/07/22/ PY - 2020/05/12/received PY - 2020/07/01/accepted PY - 2020/06/27/revised PY - 2020/7/24/entrez PY - 2020/7/24/pubmed PY - 2020/8/4/medline KW - Acute respiratory distress syndrome KW - COVID-19 KW - Cell therapy KW - Clinical trials KW - Mesenchymal stem cells SP - 305 EP - 305 JF - Stem cell research & therapy JO - Stem Cell Res Ther VL - 11 IS - 1 N2 - Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologically active factors. In this review, we will focus on clinical progress in the use of MSCs as a cell therapy for ARDS, which may have clinical implications during the coronavirus disease 2019 (COVID-19) pandemic. SN - 1757-6512 UR - https://www.unboundmedicine.com/medline/citation/32698898/Mesenchymal_stem_cells:_current_clinical_progress_in_ARDS_and_COVID_19_ L2 - https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01804-6 DB - PRIME DP - Unbound Medicine ER -